Bowel and Anal Effects of GLP-1 Drugs in People With Severe Obesity
Looks at anal and bowel changes in adults with severe obesity taking GLP-1 drugs.
Plain-language title generated from the registry record
Registry title: GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
Key facts
- Where
- Ankara, TürkiyeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with morbid obesity who have just been prescribed a GLP-1 receptor agonist medicine. It checks for bowel and anal problems at the start and after 3 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Morbid obesity: BMI of 40 kg/m² or more, or BMI of 35 kg/m² or more with health problems linked to obesity.
- Earlier treatment
- GLP-1 receptor agonist therapy must be newly prescribed.
Main reasons for not taking part
- Inflammatory bowel disease
- Perianal Crohn's disease
- History of anorectal malignancy
- Previous pelvic radiotherapy
- Anorectal surgery within the previous 3 months
Read by machine on 12 November 2026.
Where in Türkiye
- Gazi University Faculty of MedicineAnkara, TürkiyeContact: mESUT Yavaş, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Gazi University
- Trial code
- NCT07668765
- Record updated
- 25 June 2026
- Original description
Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.Read full original descriptionShow less
Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment
Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.
Inclusion: Age ≥18 years; Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities); Newly prescribed GLP-1 receptor agonist therapy; Ability and willingness to provide written informed consent; Ability to attend 3-month follow-up visit.
Exclusion: Previous pelvic radiotherapy; Anorectal surgery within the previous 3 months; Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment; Inflammatory bowel disease; Perianal Crohn's disease; History of anorectal malignancy; Active anorectal infection or abscess; Pregnancy; Neurogenic bowel dysfunction; Inability to comply with follow-up visits.